inclusion criteria: * healthy individuals aged 18-59 years as well as 60 years and above who can provide legal identification (males and females are both required). * willing to participate in the study with informed consent prior to screening * negative in sars-cov-2 igg and igm test at screening. * women of childbearing potential must be using effective method of birth control for 14 days prior to the enrollment of the study vaccine/placebo and must agree to continue such precautions during the study until 30 days after the second dose of the study vaccine/placebo. * male subjects must agree to employ acceptable contraception from the day of first dose of the study vaccine/placebo until 30 days after the second dose of the study vaccine/placebo.

inclusion criteria: * healthy individuals aged 18-59 years as well as 60 years and above who can provide legal identification (males and females are both required). * willing to participate in the study with informed consent prior to screening * negative in sars-cov-2 igg and igm test at screening. * women of childbearing potential must be using effective method of birth control for 14 days prior to the enrollment of the study vaccine/placebo and must agree to continue such precautions during the study until 30 days after the second dose of the study vaccine/placebo. * male subjects must agree to employ acceptable contraception from the day of first dose of the study vaccine/placebo until 30 days after the second dose of the study vaccine/placebo.

inclusion criteria: - healthy individuals aged 18-59 years as well as 60 years and above who can provide legal identification (males and females are both required). - willing to participate in the study with informed consent prior to screening - negative in sars-cov-2 igg and igm test at screening. - women of childbearing potential must be using effective method of birth control for 14 days prior to the enrollment of the study vaccine/placebo and must agree to continue such precautions during the study until 30 days after the second dose of the study vaccine/placebo. - male subjects must agree to employ acceptable contraception from the day of first dose of the study vaccine/placebo until 30 days after the second dose of the study vaccine/placebo.

inclusion criteria: - healthy individuals aged 18-59 years as well as 60 years and above who can provide legal identification (males and females are both required). - willing to participate in the study with informed consent prior to screening - negative in sars-cov-2 igg and igm test at screening. - women of childbearing potential must be using effective method of birth control for 14 days prior to the enrollment of the study vaccine/placebo and must agree to continue such precautions during the study until 30 days after the second dose of the study vaccine/placebo. - male subjects must agree to employ acceptable contraception from the day of first dose of the study vaccine/placebo until 30 days after the second dose of the study vaccine/placebo.